Business USFDA increases inspections of Indian drug facilities, investors remain concerned Updated : January 20, 2020 02:47 PM IST In what has been a tough start for Lupin, their Vizag API manufacturing plant was inspected by the USFDA and issued 5 observations. The street seems most concerned about Lupin because the regulatory developments in 2020 join a list of already outstanding issues for the company. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.